La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Allena Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

Dec 29

Recent updates

First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment

Jul 19

Allena Pharma reschedules special meeting to approve reverse stock split, shares fall

Jul 05

Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days

Jan 08

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

Dec 29

AMMINISTRATORE DELEGATO

Allena Pharmaceuticals non ha un CEO, o non abbiamo dati su di loro.

Allena Pharmaceuticals Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Allena Pharmaceuticals, Inc. Announces Executive Changes

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

Allena Pharmaceuticals, Inc. Announces Executive Changes

Allena Pharmaceuticals, Inc. Appoints Geoffrey Swire to Serve as the Acting Chief Operating Officer and Interim Principal Operating Officer

Allena Pharmaceuticals, Inc. Announces Resignation of Edward Wholihan as Chief Financial Officer

Allena Pharmaceuticals, Inc. Announces Board Changes

Recent updates

Allena Pharmaceuticals, Inc. announced delayed 10-Q filing

Nasdaq to Delist Common Stock of Allena Pharmaceuticals

Nasdaq to Suspends Shares of Allena Pharmaceuticals on September 08, 2022

Allena Pharmaceuticals, Inc. Filed for Bankruptcy

Allena Pharmaceuticals Receives Letter from Staff

Allena Pharmaceuticals, Inc. Provides ALLN-346 Program Update

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2A Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment

Allena Pharma reschedules special meeting to approve reverse stock split, shares fall

Price target decreased to US$0.50

Price target decreased to US$0.50

Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days

Price target decreased to US$5.06

Allena Pharmaceuticals, Inc. Provides A Clinical and Corporate Update

Price target decreased to US$6.38

Allena Pharmaceuticals Provides Update on Clinical Development Programs

Allena Pharmaceuticals, Inc.(NasdaqGS:ALNA) dropped from Russell 3000E Value Index

Independent Director James Topper has left the company

Independent Director Andrew A. Hack has left the company

Price target increased to US$7.00

Price target raised to US$7.00

Allena Pharmaceuticals, Inc. Announces Executive Changes

Chief Financial Officer has left the company

Allena Pharmaceuticals, Inc.(NasdaqGS:ALNA) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.64

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

Allena Pharmaceuticals, Inc. Announces Executive Changes

Allena Pharmaceuticals announces $10M bought deal

Allena Pharmaceuticals, Inc. Announces Initial Data from Phase 1 Trial of ALLN-346

Allena Pharma's ALLN-346 shows encouraging action in early-stage study

Price target lowered to US$5.83

Allena Pharmaceuticals, Inc. Appoints Geoffrey Swire to Serve as the Acting Chief Operating Officer and Interim Principal Operating Officer

Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow

Price target raised to US$9.20

Allena Pharmaceuticals, Inc. Announces Resignation of Edward Wholihan as Chief Financial Officer

Allena Pharmaceuticals EPS misses by $0.01

Allena Pharmaceuticals, Inc. Announces Board Changes

Allena Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Pontifax Medison Finance (Israel) L.P., Pontifax Medison Finance (Cayman) L.P.

Allena Pharmaceuticals, Inc. announced that it has received $15 million in funding from Bessemer Venture Partners, Frazier Healthcare Partners, Third Rock Ventures, LLC and other investors

New 90-day low - US$1.16

Allena Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

New 90-day low - US$1.30

AMMINISTRATORE DELEGATO